F9

Across TCGA pan-cancer cohorts, F9 RNA is linked to patient survival in 11 of 34 cancer types, making it the most broadly survival-associated F9 data layer compared with 2 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher F9 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated F9 expression acts as an unfavorable survival marker, although some lineages such as LIHC and ESCA show a favorable association.

LIHC, LUAD, and ESCA are the cancer types where F9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.615	0.468	<.001	70	view →
LUAD	DFS	Tertile	All	0.344	0.689	<.001	66	view →
ESCA	OS	Tertile	All	0.802	0.422	.009	63	view →
CHOL	DFS	Median	II,III,IV	0.107	0.546	.008	53	view →
ACC	DFS	Tertile	All	1.000	0.401	.014	30	view →
BLCA	DFS	Tertile	All	0.709	0.271	.024	30	view →
SCLC	DFS	Tertile	All	0.274	0.815	.013	18	view →
THYM	OS	Tertile	II,III,IV	0.700	0.960	.025	18	view →
STAD	DFS	Tertile	IV	0.160	0.402	.044	9	view →
BRCA	OS	Tertile	All	0.883	0.929	.033	6	view →
COAD	OS	Tertile	IV	1.000	0.452	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

F9–LIHC (DFS)

Open the LIHC breakdown →